Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Pfizer (NYSE:PFE) announced Saturday that its colorectal cancer therapy Braftovi, as part of a combination regimen, reduced tumor size (confirmed objective response rate) in a late-stage trial with a ...

A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the ...

SELLAS Life Sciences CEO Angelos Stergiou and "Some Future Day" author Marc Beckman predict artificial intelligence will ...

Scientists at The Hospital for Sick Children (SickKids) have identified a key gene that could lead to next-generation treatments for medulloblastoma, the most common malignant brain tumor in children.

Researchers have created an ultra-fast cancer treatment that can deliver much-needed treatment in just one second.

The blood–brain barrier is a highly selective shield that protects the brain from harmful substances in the bloodstream.